Kovitz Investment Group Partners LLC Invests $1.93 Million in DexCom, Inc. (NASDAQ:DXCM)

Kovitz Investment Group Partners LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 24,747 shares of the medical device company's stock, valued at approximately $1,925,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC raised its stake in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC raised its position in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $38,000. Institutional investors own 97.75% of the company's stock.

DexCom Price Performance

DexCom stock traded down $1.12 during trading hours on Thursday, hitting $70.26. The stock had a trading volume of 6,865,096 shares, compared to its average volume of 4,222,913. The stock has a market capitalization of $27.55 billion, a price-to-earnings ratio of 49.13, a PEG ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.26. The stock's fifty day moving average is $72.01 and its two-hundred day moving average is $76.67.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. During the same quarter in the previous year, the company posted $0.32 EPS. The firm's quarterly revenue was up 12.5% on a year-over-year basis. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on DXCM. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Citigroup raised their target price on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Mizuho assumed coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $99.00.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.